DataMeds AI Reports Nasdaq Equity Rule Compliance, With Next Filing Still Relevant
DataMeds AI received Nasdaq confirmation that it had met the minimum stockholders’ equity requirement under Listing Rule 5550(b)(1). The company said it may still be subject to delisting if its next periodic report does not evidence compliance.
DataMeds AI, Inc. (NASDAQ:MEDS) said Nasdaq confirmed that the company had restored compliance with Listing Rule 5550(b)(1), known as the Equity Rule. The confirmation was issued on October 19, 2026, and announced by DataMeds AI on October 20, 2026.
To meet the rule, DataMeds AI needed minimum stockholders’ equity of $2.5 million. The company’s Form 8-K filed on October 13, 2026, reported that stockholders’ equity exceeded $2,500,000. A further Form 8-K filed on October 16, 2026, described the material events associated with the increase.
Nasdaq subsequently notified the company on October 19, 2026, that it was compliant with the Equity Rule.
DataMeds AI said it received a delisting notice from NASDAQ on April 13, 2026. The company was later notified on June 9, 2026, that it had regained compliance with the bid-price requirement. Nasdaq also gave the company additional time to address the separate minimum stockholders’ equity standard.
Despite the latest compliance notice, DataMeds AI said it may be subject to delisting if it fails to evidence compliance when it files its next periodic report.
DataMeds AI, which also uses the name DataMeds SI, describes itself as a healthcare company combining Health IT, pharmacy, pharmaceutical-adjacent and telemedicine operations. Its platforms include EinsteinRx™, a super intelligence platform, and PharmacyChain™, a blockchain-enabled smart contracts platform, which the company incorporates into its Health Lives Here mobile application.
The company said its Corexa Pharmacy provides dispensing and related services, including distribution of products developed by Tollo Health. Its Helomics Corporation subsidiary operates a CLIA-certified laboratory in Pittsburgh offering the ChemoFx® Assay. DataMeds AI also said it has licensed patented GLP-1 patient management technology from REBOOT, a subsidiary of Data Health Partners.
DataMeds AI said its forward-looking statements reflect management’s current expectations and are not predictions of actual performance. The company cautioned that results may differ materially because of risks and uncertainties, and said those statements apply only as of the date of its announcement.
DataMeds AI announced that it had received a Compliance Notice from the Listing Qualifications Staff of the Nasdaq Stock Market, LLC confirming that it had regained compliance with Nasdaq Listing Rule 5550(b)(1), known as the Equity Rule. The Compliance Notice was dated October 19, 2026.
DataMeds AI regained compliance with Nasdaq Listing Rule 5550(b)(1), the Equity Rule. The company needed to have minimum stockholders' equity of $2.5 million to meet the requirement.
DataMeds AI demonstrated compliance through a Form 8-K filed on October 13, 2026, which confirmed that its stockholders' equity exceeded $2,500,000. A subsequent Form 8-K filed on October 16, 2026, provided additional details on the material events that resulted in stockholders' equity exceeding $2,500,000.
DataMeds AI said Nasdaq confirmed its compliance with the Equity Rule on October 19, 2026. The company announced the confirmation on October 20, 2026.
DataMeds AI originally received a notice of delisting from NASDAQ on April 13, 2026. The notice outlined the basis for delisting proceedings, including the company's failure at that time to meet the minimum stockholders' equity requirement.
Yes. DataMeds AI said NASDAQ notified it on June 9, 2026, that it had regained bid-price compliance and provided additional time to attempt to regain compliance with the minimum stockholders' equity requirement.
Yes. DataMeds AI said that if it fails to evidence compliance upon filing its next periodic report, it may be subject to delisting.
DataMeds AI trades on the Nasdaq Stock Market, LLC under the ticker symbol NASDAQ:MEDS. The company also describes itself as DataMeds SI, with the ticker shown as NASDAQ:MEDS.
DataMeds AI is a healthcare company focused on the vertical integration of technology, pharmacy, pharmaceutical-adjacent and telemedicine business units through its Health IT platforms. It says the platforms are intended to deliver a better experience for consumers and providers.
DataMeds AI incorporates the super intelligence platform EinsteinRx™ and the blockchain-enabled smart contracts platform PharmacyChain™ into its Health Lives Here mobile application. The company also identifies its business as including Health IT and physical infrastructure.
DataMeds AI says its Corexa Pharmacy provides pharmacy dispensing and related services, including distribution of products developed by Tollo Health. Its Helomics Corporation subsidiary operates a CLIA-certified laboratory in Pittsburgh offering the ChemoFx® Assay, and the company has licensed patented GLP-1 patient management technology from REBOOT, a subsidiary of Data Health Partners.
DataMeds AI said its forward-looking statements are based on management's current expectations and are not predictions of actual performance. It cautioned that actual results may differ materially because of risks and uncertainties, and said the statements speak only as of the date of the press release.